WELLVONE

This brand name is authorized in Australia, Estonia, France, Netherlands, South Africa, Spain, UK.

Active ingredients

The drug WELLVONE contains one active pharmaceutical ingredient (API):

1	Atovaquone UNII Y883P1Z2LT - ATOVAQUONE
	Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III).
	Read more about Atovaquone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WELLVONE Oral suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01AX06	Atovaquone	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01A Agents against amoebiasis and other protozoal diseases → P01AX Other agents against amoebiasis and other protozoal diseases
Discover more medicines within P01AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8300W
EE	Ravimiamet	1773110
ES	Centro de información online de medicamentos de la AEMPS	63390
FR	Base de données publique des médicaments	66955317
GB	Medicines & Healthcare Products Regulatory Agency	165909
NL	Z-Index G-Standaard	14249642
NL	Z-Index G-Standaard, PRK	47147
ZA	Health Products Regulatory Authority	31/20.2.6/0033